A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or ...

An award-winning pathologist who devoted his life to melanoma research became the first person to receive a novel ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

A novel cell therapy approach using natural killer cells pre-complexed with a bispecific antibody, was safe and generated ...

The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning ...

Ociperlimab is described as a humanised IgG1 monoclonal antibody with the potential to enhance T cell-mediated immune ...

Fintel reports that on April 2, 2025, Lake Street initiated coverage of OS Therapies (NYSEAM:OSTX) with a Buy recommendation. Analyst Price Forecast Suggests 865.16% Upside As of March 19, 2025, the ...

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Compass Therapeutics (NASDAQ:CMPX) stock gains as its oncology drug tovecimig hits main goal in a Phase 2/3 trial for biliary ...